What treating Ebola means for pandemic influenza.
Identifieur interne : 000279 ( PubMed/Curation ); précédent : 000278; suivant : 000280What treating Ebola means for pandemic influenza.
Auteurs : David S. Fedson [France]Source :
- Journal of public health policy [ 1745-655X ] ; 2018.
Descripteurs français
- KwdFr :
- Analyse de survie, Antagonistes des récepteurs aux angiotensines (usage thérapeutique), Antagonistes des récepteurs aux angiotensines (économie), Association médicamenteuse, Essais cliniques comme sujet, Fièvre hémorragique à virus Ebola (traitement médicamenteux), Fièvre hémorragique à virus Ebola (épidémiologie), Grippe humaine (), Grippe humaine (épidémiologie), Humains, Inhibiteurs de l'hydroxyméthylglutaryl-CoA réductase (usage thérapeutique), Inhibiteurs de l'hydroxyméthylglutaryl-CoA réductase (économie), Médicaments génériques (ressources et distribution), Médicaments génériques (usage thérapeutique), Médicaments génériques (économie), Pandémies (), Santé mondiale, Thérapie moléculaire ciblée.
- MESH :
- ressources et distribution : Médicaments génériques.
- traitement médicamenteux : Fièvre hémorragique à virus Ebola.
- usage thérapeutique : Antagonistes des récepteurs aux angiotensines, Inhibiteurs de l'hydroxyméthylglutaryl-CoA réductase, Médicaments génériques.
- économie : Antagonistes des récepteurs aux angiotensines, Inhibiteurs de l'hydroxyméthylglutaryl-CoA réductase, Médicaments génériques.
- épidémiologie : Fièvre hémorragique à virus Ebola, Grippe humaine.
- Analyse de survie, Association médicamenteuse, Essais cliniques comme sujet, Grippe humaine, Humains, Pandémies, Santé mondiale, Thérapie moléculaire ciblée.
English descriptors
- KwdEn :
- Angiotensin Receptor Antagonists (economics), Angiotensin Receptor Antagonists (therapeutic use), Clinical Trials as Topic, Drug Combinations, Drugs, Generic (economics), Drugs, Generic (supply & distribution), Drugs, Generic (therapeutic use), Global Health, Hemorrhagic Fever, Ebola (drug therapy), Hemorrhagic Fever, Ebola (epidemiology), Humans, Hydroxymethylglutaryl-CoA Reductase Inhibitors (economics), Hydroxymethylglutaryl-CoA Reductase Inhibitors (therapeutic use), Influenza, Human (epidemiology), Influenza, Human (prevention & control), Molecular Targeted Therapy, Pandemics (prevention & control), Survival Analysis.
- MESH :
- chemical , economics : Angiotensin Receptor Antagonists, Drugs, Generic, Hydroxymethylglutaryl-CoA Reductase Inhibitors.
- chemical , supply & distribution : Drugs, Generic.
- chemical , therapeutic use : Angiotensin Receptor Antagonists, Drugs, Generic, Hydroxymethylglutaryl-CoA Reductase Inhibitors.
- drug therapy : Hemorrhagic Fever, Ebola.
- epidemiology : Hemorrhagic Fever, Ebola, Influenza, Human.
- prevention & control : Influenza, Human, Pandemics.
- Clinical Trials as Topic, Drug Combinations, Global Health, Humans, Molecular Targeted Therapy, Survival Analysis.
Abstract
Almost all new treatments being developed for the next influenza pandemic target the virus. During the Ebola crisis in West Africa, patients were treated with an inexpensive generic statin/angiotensin receptor blocker combination that appeared to greatly improve survival. These drugs target the host response, not the virus, and probably reverse endothelial dysfunction. Scientists and health officials have shown little interest in this idea. Yet, during the early months of the next pandemic, vaccines will be unavailable and treatment options will be limited. Physicians should be prepared to undertake clinical trials of widely available generic drugs to determine whether they improve survival in patients with seasonal influenza, other emerging virus diseases, and other forms of acute critical illness. Public health officials should give these studies their strong support. If successful, they will suggest a 'bottom up' approach to patient care that could be implemented worldwide on the first pandemic day.
DOI: 10.1057/s41271-018-0138-8
PubMed: 30013135
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: Pour aller vers cette notice dans l'étape Curation :000279
Links to Exploration step
pubmed:30013135Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">What treating Ebola means for pandemic influenza.</title><author><name sortKey="Fedson, David S" sort="Fedson, David S" uniqKey="Fedson D" first="David S" last="Fedson">David S. Fedson</name><affiliation wicri:level="1"><nlm:affiliation>, 57, chemin du Lavoir, 01630, Sergy Haut, France. davidsfedson@gmail.com.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>, 57, chemin du Lavoir, 01630, Sergy Haut</wicri:regionArea></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2018">2018</date><idno type="RBID">pubmed:30013135</idno><idno type="pmid">30013135</idno><idno type="doi">10.1057/s41271-018-0138-8</idno><idno type="wicri:Area/PubMed/Corpus">000279</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000279</idno><idno type="wicri:Area/PubMed/Curation">000279</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000279</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">What treating Ebola means for pandemic influenza.</title><author><name sortKey="Fedson, David S" sort="Fedson, David S" uniqKey="Fedson D" first="David S" last="Fedson">David S. Fedson</name><affiliation wicri:level="1"><nlm:affiliation>, 57, chemin du Lavoir, 01630, Sergy Haut, France. davidsfedson@gmail.com.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>, 57, chemin du Lavoir, 01630, Sergy Haut</wicri:regionArea></affiliation></author></analytic><series><title level="j">Journal of public health policy</title><idno type="eISSN">1745-655X</idno><imprint><date when="2018" type="published">2018</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Angiotensin Receptor Antagonists (economics)</term><term>Angiotensin Receptor Antagonists (therapeutic use)</term><term>Clinical Trials as Topic</term><term>Drug Combinations</term><term>Drugs, Generic (economics)</term><term>Drugs, Generic (supply & distribution)</term><term>Drugs, Generic (therapeutic use)</term><term>Global Health</term><term>Hemorrhagic Fever, Ebola (drug therapy)</term><term>Hemorrhagic Fever, Ebola (epidemiology)</term><term>Humans</term><term>Hydroxymethylglutaryl-CoA Reductase Inhibitors (economics)</term><term>Hydroxymethylglutaryl-CoA Reductase Inhibitors (therapeutic use)</term><term>Influenza, Human (epidemiology)</term><term>Influenza, Human (prevention & control)</term><term>Molecular Targeted Therapy</term><term>Pandemics (prevention & control)</term><term>Survival Analysis</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Analyse de survie</term><term>Antagonistes des récepteurs aux angiotensines (usage thérapeutique)</term><term>Antagonistes des récepteurs aux angiotensines (économie)</term><term>Association médicamenteuse</term><term>Essais cliniques comme sujet</term><term>Fièvre hémorragique à virus Ebola (traitement médicamenteux)</term><term>Fièvre hémorragique à virus Ebola (épidémiologie)</term><term>Grippe humaine ()</term><term>Grippe humaine (épidémiologie)</term><term>Humains</term><term>Inhibiteurs de l'hydroxyméthylglutaryl-CoA réductase (usage thérapeutique)</term><term>Inhibiteurs de l'hydroxyméthylglutaryl-CoA réductase (économie)</term><term>Médicaments génériques (ressources et distribution)</term><term>Médicaments génériques (usage thérapeutique)</term><term>Médicaments génériques (économie)</term><term>Pandémies ()</term><term>Santé mondiale</term><term>Thérapie moléculaire ciblée</term></keywords><keywords scheme="MESH" type="chemical" qualifier="economics" xml:lang="en"><term>Angiotensin Receptor Antagonists</term><term>Drugs, Generic</term><term>Hydroxymethylglutaryl-CoA Reductase Inhibitors</term></keywords><keywords scheme="MESH" type="chemical" qualifier="supply & distribution" xml:lang="en"><term>Drugs, Generic</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Angiotensin Receptor Antagonists</term><term>Drugs, Generic</term><term>Hydroxymethylglutaryl-CoA Reductase Inhibitors</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Hemorrhagic Fever, Ebola</term></keywords><keywords scheme="MESH" qualifier="epidemiology" xml:lang="en"><term>Hemorrhagic Fever, Ebola</term><term>Influenza, Human</term></keywords><keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>Influenza, Human</term><term>Pandemics</term></keywords><keywords scheme="MESH" qualifier="ressources et distribution" xml:lang="fr"><term>Médicaments génériques</term></keywords><keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Fièvre hémorragique à virus Ebola</term></keywords><keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Antagonistes des récepteurs aux angiotensines</term><term>Inhibiteurs de l'hydroxyméthylglutaryl-CoA réductase</term><term>Médicaments génériques</term></keywords><keywords scheme="MESH" qualifier="économie" xml:lang="fr"><term>Antagonistes des récepteurs aux angiotensines</term><term>Inhibiteurs de l'hydroxyméthylglutaryl-CoA réductase</term><term>Médicaments génériques</term></keywords><keywords scheme="MESH" qualifier="épidémiologie" xml:lang="fr"><term>Fièvre hémorragique à virus Ebola</term><term>Grippe humaine</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Clinical Trials as Topic</term><term>Drug Combinations</term><term>Global Health</term><term>Humans</term><term>Molecular Targeted Therapy</term><term>Survival Analysis</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Analyse de survie</term><term>Association médicamenteuse</term><term>Essais cliniques comme sujet</term><term>Grippe humaine</term><term>Humains</term><term>Pandémies</term><term>Santé mondiale</term><term>Thérapie moléculaire ciblée</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Almost all new treatments being developed for the next influenza pandemic target the virus. During the Ebola crisis in West Africa, patients were treated with an inexpensive generic statin/angiotensin receptor blocker combination that appeared to greatly improve survival. These drugs target the host response, not the virus, and probably reverse endothelial dysfunction. Scientists and health officials have shown little interest in this idea. Yet, during the early months of the next pandemic, vaccines will be unavailable and treatment options will be limited. Physicians should be prepared to undertake clinical trials of widely available generic drugs to determine whether they improve survival in patients with seasonal influenza, other emerging virus diseases, and other forms of acute critical illness. Public health officials should give these studies their strong support. If successful, they will suggest a 'bottom up' approach to patient care that could be implemented worldwide on the first pandemic day.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">30013135</PMID><DateCompleted><Year>2018</Year><Month>11</Month><Day>21</Day></DateCompleted><DateRevised><Year>2020</Year><Month>04</Month><Day>01</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1745-655X</ISSN><JournalIssue CitedMedium="Internet"><Volume>39</Volume><Issue>3</Issue><PubDate><Year>2018</Year><Month>Aug</Month></PubDate></JournalIssue><Title>Journal of public health policy</Title><ISOAbbreviation>J Public Health Policy</ISOAbbreviation></Journal><ArticleTitle>What treating Ebola means for pandemic influenza.</ArticleTitle><Pagination><MedlinePgn>268-282</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1057/s41271-018-0138-8</ELocationID><Abstract><AbstractText>Almost all new treatments being developed for the next influenza pandemic target the virus. During the Ebola crisis in West Africa, patients were treated with an inexpensive generic statin/angiotensin receptor blocker combination that appeared to greatly improve survival. These drugs target the host response, not the virus, and probably reverse endothelial dysfunction. Scientists and health officials have shown little interest in this idea. Yet, during the early months of the next pandemic, vaccines will be unavailable and treatment options will be limited. Physicians should be prepared to undertake clinical trials of widely available generic drugs to determine whether they improve survival in patients with seasonal influenza, other emerging virus diseases, and other forms of acute critical illness. Public health officials should give these studies their strong support. If successful, they will suggest a 'bottom up' approach to patient care that could be implemented worldwide on the first pandemic day.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Fedson</LastName><ForeName>David S</ForeName><Initials>DS</Initials><AffiliationInfo><Affiliation>, 57, chemin du Lavoir, 01630, Sergy Haut, France. davidsfedson@gmail.com.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>J Public Health Policy</MedlineTA><NlmUniqueID>8006508</NlmUniqueID><ISSNLinking>0197-5897</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D057911">Angiotensin Receptor Antagonists</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004338">Drug Combinations</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016568">Drugs, Generic</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D019161">Hydroxymethylglutaryl-CoA Reductase Inhibitors</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D057911" MajorTopicYN="N">Angiotensin Receptor Antagonists</DescriptorName><QualifierName UI="Q000191" MajorTopicYN="N">economics</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002986" MajorTopicYN="N">Clinical Trials as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004338" MajorTopicYN="N">Drug Combinations</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016568" MajorTopicYN="N">Drugs, Generic</DescriptorName><QualifierName UI="Q000191" MajorTopicYN="N">economics</QualifierName><QualifierName UI="Q000600" MajorTopicYN="N">supply & distribution</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014943" MajorTopicYN="N">Global Health</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019142" MajorTopicYN="N">Hemorrhagic Fever, Ebola</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019161" MajorTopicYN="N">Hydroxymethylglutaryl-CoA Reductase Inhibitors</DescriptorName><QualifierName UI="Q000191" MajorTopicYN="N">economics</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007251" MajorTopicYN="N">Influenza, Human</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention & control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D058990" MajorTopicYN="Y">Molecular Targeted Therapy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D058873" MajorTopicYN="N">Pandemics</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention & control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016019" MajorTopicYN="N">Survival Analysis</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Angiotensin receptor blockers</Keyword><Keyword MajorTopicYN="N">Ebola</Keyword><Keyword MajorTopicYN="N">Emerging virus diseases</Keyword><Keyword MajorTopicYN="N">Endothelial dysfunction</Keyword><Keyword MajorTopicYN="N">Host response</Keyword><Keyword MajorTopicYN="N">Pandemic influenza</Keyword><Keyword MajorTopicYN="N">Statins</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2018</Year><Month>7</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2018</Year><Month>11</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2018</Year><Month>7</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">30013135</ArticleId><ArticleId IdType="doi">10.1057/s41271-018-0138-8</ArticleId><ArticleId IdType="pii">10.1057/s41271-018-0138-8</ArticleId><ArticleId IdType="pmc">PMC7102163</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Clin Infect Dis. 2006 Jul 15;43(2):199-205</Citation><ArticleIdList><ArticleId IdType="pubmed">16779747</ArticleId></ArticleIdList></Reference><Reference><Citation>J Infect Dis. 2015 Feb 15;211(4):661-2</Citation><ArticleIdList><ArticleId IdType="pubmed">25160984</ArticleId></ArticleIdList></Reference><Reference><Citation>N Engl J Med. 2016 Jan 7;374(1):23-32</Citation><ArticleIdList><ArticleId IdType="pubmed">26735991</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet. 2017 Feb 4;389(10068):505-518</Citation><ArticleIdList><ArticleId IdType="pubmed">28017403</ArticleId></ArticleIdList></Reference><Reference><Citation>Curr Ther Res Clin Exp. 2017 Feb 02;84:10-21</Citation><ArticleIdList><ArticleId IdType="pubmed">28761574</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet Infect Dis. 2017 Sep;17(9):e280-e292</Citation><ArticleIdList><ArticleId IdType="pubmed">28461209</ArticleId></ArticleIdList></Reference><Reference><Citation>BMJ. 2007 Feb 17;334(7589):349-51</Citation><ArticleIdList><ArticleId IdType="pubmed">17303884</ArticleId></ArticleIdList></Reference><Reference><Citation>EMBO Rep. 2015 Aug;16(8):902-5</Citation><ArticleIdList><ArticleId IdType="pubmed">26169390</ArticleId></ArticleIdList></Reference><Reference><Citation>Science. 2014 Aug 15;345(6198):718-9</Citation><ArticleIdList><ArticleId IdType="pubmed">25124404</ArticleId></ArticleIdList></Reference><Reference><Citation>N Engl J Med. 2016 Feb 18;374(7):636-46</Citation><ArticleIdList><ArticleId IdType="pubmed">26886522</ArticleId></ArticleIdList></Reference><Reference><Citation>PLoS Med. 2016 May 19;13(5):e1002042</Citation><ArticleIdList><ArticleId IdType="pubmed">27195954</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Mol Med. 2014 Jul;34(1):61-73</Citation><ArticleIdList><ArticleId IdType="pubmed">24788303</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Public Health. 2005;95 Suppl 1:S144-50</Citation><ArticleIdList><ArticleId IdType="pubmed">16030331</ArticleId></ArticleIdList></Reference><Reference><Citation>N Engl J Med. 2014 Apr 3;370(14):1335-42</Citation><ArticleIdList><ArticleId IdType="pubmed">24693893</ArticleId></ArticleIdList></Reference><Reference><Citation>Malar Res Treat. 2012;2012:679090</Citation><ArticleIdList><ArticleId IdType="pubmed">23097741</ArticleId></ArticleIdList></Reference><Reference><Citation>Circ J. 2014;78(2):281-7</Citation><ArticleIdList><ArticleId IdType="pubmed">24401609</ArticleId></ArticleIdList></Reference><Reference><Citation>Sci Transl Med. 2017 Aug 9;9(402):</Citation><ArticleIdList><ArticleId IdType="pubmed">28794286</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet Infect Dis. 2017 Aug;17(8):822-832</Citation><ArticleIdList><ArticleId IdType="pubmed">28583578</ArticleId></ArticleIdList></Reference><Reference><Citation>mBio. 2015 Jun 23;6(3):e00716</Citation><ArticleIdList><ArticleId IdType="pubmed">26106080</ArticleId></ArticleIdList></Reference><Reference><Citation>Crit Care Med. 2018 Mar;46(3):442-446</Citation><ArticleIdList><ArticleId IdType="pubmed">29474325</ArticleId></ArticleIdList></Reference><Reference><Citation>Ann Transl Med. 2016 Nov;4(21):421</Citation><ArticleIdList><ArticleId IdType="pubmed">27942512</ArticleId></ArticleIdList></Reference><Reference><Citation>PLoS One. 2017 Jan 17;12(1):e0168975</Citation><ArticleIdList><ArticleId IdType="pubmed">28095476</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Commun. 2015 Jul 09;6:7688</Citation><ArticleIdList><ArticleId IdType="pubmed">26158910</ArticleId></ArticleIdList></Reference><Reference><Citation>Emerg Infect Dis. 2009 Mar;15(3):365-71</Citation><ArticleIdList><ArticleId IdType="pubmed">19239746</ArticleId></ArticleIdList></Reference><Reference><Citation>Vaccine. 2017 Aug 24;35(36):4681-4686</Citation><ArticleIdList><ArticleId IdType="pubmed">28754488</ArticleId></ArticleIdList></Reference><Reference><Citation>Antiviral Res. 2013 Sep;99(3):417-35</Citation><ArticleIdList><ArticleId IdType="pubmed">23831494</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Infect Dis. 2016 Oct 15;63(8):1026-33</Citation><ArticleIdList><ArticleId IdType="pubmed">27531847</ArticleId></ArticleIdList></Reference><Reference><Citation>Ann Intern Med. 2001 Feb 20;134(4):330-4</Citation><ArticleIdList><ArticleId IdType="pubmed">11182844</ArticleId></ArticleIdList></Reference><Reference><Citation>Vaccine. 2016 Oct 26;34(45):5391-5392</Citation><ArticleIdList><ArticleId IdType="pubmed">27682508</ArticleId></ArticleIdList></Reference><Reference><Citation>PLoS Med. 2016 Mar 01;13(3):e1001967</Citation><ArticleIdList><ArticleId IdType="pubmed">26930627</ArticleId></ArticleIdList></Reference><Reference><Citation>Science. 2016 Jan 1;351(6268):12-3</Citation><ArticleIdList><ArticleId IdType="pubmed">26721981</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Infect Dis. 2014 Jan;58(2):233-7</Citation><ArticleIdList><ArticleId IdType="pubmed">24145877</ArticleId></ArticleIdList></Reference><Reference><Citation>Hum Vaccin Immunother. 2018 Mar 4;14(3):790-795</Citation><ArticleIdList><ArticleId IdType="pubmed">29058516</ArticleId></ArticleIdList></Reference><Reference><Citation>Sci Rep. 2015 Jun 05;5:11030</Citation><ArticleIdList><ArticleId IdType="pubmed">26046800</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet. 2017 Jun 24;389(10088):2469-2470</Citation><ArticleIdList><ArticleId IdType="pubmed">28656895</ArticleId></ArticleIdList></Reference><Reference><Citation>Risk Manag Healthc Policy. 2016 May 12;9:55-65</Citation><ArticleIdList><ArticleId IdType="pubmed">27274326</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Infect Dis. 2015 Jul;36:80-4</Citation><ArticleIdList><ArticleId IdType="pubmed">26143190</ArticleId></ArticleIdList></Reference><Reference><Citation>N Engl J Med. 2017 Aug 3;377(5):465-475</Citation><ArticleIdList><ArticleId IdType="pubmed">28767357</ArticleId></ArticleIdList></Reference><Reference><Citation>J Infect Dis. 2017 Jan 15;215(2):167-170</Citation><ArticleIdList><ArticleId IdType="pubmed">28073859</ArticleId></ArticleIdList></Reference><Reference><Citation>Ann Intern Med. 2006 Jul 18;145(2):138-40</Citation><ArticleIdList><ArticleId IdType="pubmed">16801626</ArticleId></ArticleIdList></Reference><Reference><Citation>N Engl J Med. 2017 Feb 16;376(7):610-613</Citation><ArticleIdList><ArticleId IdType="pubmed">28099066</ArticleId></ArticleIdList></Reference><Reference><Citation>Crit Care. 2016 Jul 29;20(1):217</Citation><ArticleIdList><ArticleId IdType="pubmed">27468829</ArticleId></ArticleIdList></Reference><Reference><Citation>mBio. 2018 May 1;9(3):</Citation><ArticleIdList><ArticleId IdType="pubmed">29717011</ArticleId></ArticleIdList></Reference><Reference><Citation>BMC Med Ethics. 2017 Jun 26;18(1):43</Citation><ArticleIdList><ArticleId IdType="pubmed">28651650</ArticleId></ArticleIdList></Reference><Reference><Citation>Front Immunol. 2015 Aug 31;6:432</Citation><ArticleIdList><ArticleId IdType="pubmed">26379668</ArticleId></ArticleIdList></Reference><Reference><Citation>J Crit Care. 2017 Aug;40:7-10</Citation><ArticleIdList><ArticleId IdType="pubmed">28288355</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Rev Immunol. 2017 Feb;17(2):83-96</Citation><ArticleIdList><ArticleId IdType="pubmed">28044057</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet. 2017 Jun 24;389(10088):2455-2457</Citation><ArticleIdList><ArticleId IdType="pubmed">28656892</ArticleId></ArticleIdList></Reference><Reference><Citation>J Public Health Policy. 2007;28(3):322-40</Citation><ArticleIdList><ArticleId IdType="pubmed">17717543</ArticleId></ArticleIdList></Reference><Reference><Citation>Immunity. 2015 Sep 15;43(3):421-34</Citation><ArticleIdList><ArticleId IdType="pubmed">26377896</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/PandemieGrippaleV1/Data/PubMed/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000279 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd -nk 000279 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= PandemieGrippaleV1
|flux= PubMed
|étape= Curation
|type= RBID
|clé= pubmed:30013135
|texte= What treating Ebola means for pandemic influenza.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Curation/RBID.i -Sk "pubmed:30013135" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd \
| NlmPubMed2Wicri -a PandemieGrippaleV1
| This area was generated with Dilib version V0.6.34. |  |